FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.
FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.
复制标题
FOLFOX4 作为老年结肠癌 (CC) 患者 (pts) 的辅助治疗：MOSAIC 试验的亚组分析。
DOI：
10.1200/jco.2010.28.15_suppl.3522
复制
发表时间：
2010
影响因子：
45.3
通讯作者：
Gercor
中科院分区：
文献类型：
--
作者：
C. Tournigand;T. André;J. Bachet;L. Teixeira;C. Boni;P. Clingan;T. Hickish;J. Tabernero;A. Gramont;Gercor
3522背景：在老年CC患者中，基于5 FU的辅助化疗可增加总生存期（OS）和无病生存期（DFS）（萨金特，NEJM 2001）。FOLFOX 4改善了III期的DFS和OS（Andre，JCO 2009）。在NSABP-C 07和MOSAIC试验的汇总分析中，在≥ 70岁的患者中，基于奥沙利铂/5 FU的化疗不优于5 FU/LV（上级）（杰克逊Mc Cleary，ASCO 2009）。研究方法：我们对MOSAIC试验中年龄≥ 70岁的患者进行了亚组分析，根据成人合并症评价-27、SAE、第二种癌症和死亡原因审查了临床特征、合并症。结果：315例≥ 70岁的患者被随机分配至FOLFOX 4（155例患者）和LV 5 FU 2（160例患者）组。中位随访时间为6年。DFS风险比（HR）为0.91; 95%置信区间（CI）为0.62 - 1.34，OS HR为1.10; 95% CI为0.73 - 1.65。未观察到初始特征的不平衡。在FOLFOX 4组和LV 5 FU 2组中，59例和66例患者为II期，38例和42例为高风险II期（pT 4和/或< 12个淋巴结），96例和9例为高风险II期（pT 4和/或< 12个淋巴结）。
3522 Background: In elderly CC pts, adjuvant 5FU-based chemotherapy increases overall survival (OS) and disease-free survival (DFS) (Sargent, NEJM 2001). FOLFOX4 improved DFS and OS in stage III (Andre, JCO 2009). In a pooled analysis of NSABP-C07 and MOSAIC trials, oxaliplatin/5FU-based chemotherapy was not superior to 5FU/LV in pts ≥ 70 years (Jackson Mc Cleary, ASCO 2009). Methods: We performed a subgroup analysis of pts aged ≥ 70 yrs in the MOSAIC trial, reviewing clinical characteristics, comorbidities according to Adult Comorbidity Evaluation-27, SAEs, 2nd cancer and cause of death. Results: 315 pts ≥ 70 yrs were randomized between FOLFOX4 (155 pts) and LV5FU2 (160 pts). Median follow-up was 6 yrs. DFS hazard ratio (HR) was 0.91; 95% confidence interval (CI) 0.62 to 1.34 and OS HR was 1.10; 95% CI 0.73 to 1.65. No imbalance was observed for initial characteristics. In the FOLFOX4 arm and the LV5FU2 arm, 59 and 66 pts were stage II, 38 and 42 high risk stage II (pT4 and/or < 12 lymph nodes), 96 and 9...